Daily collagen peptides for cellular aging in middle-aged adults
Official title: Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults
Run by University of Vienna · NCT07456449 · Data updated 2026-11-12
This trial will test whether taking daily collagen peptides for 24 weeks can stabilize or lengthen telomeres and improve cellular aging markers in adults aged 50–70 with overweight and low-to-moderate physical activity.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 70 Years |
| Sex | All |
| Enrollment | 125 (estimated) |
| Sponsor | University of Vienna Academic / other |
| Locations | 1 site (Vienna, State of Vienna) |
| Status | Recruiting |
| Started | April 22, 2026 |
| Main results expected | February 2028 |
| Study ends | August 2028 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07456449 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–70 years with BMI 25–30 kg/m², low-to-moderate physical activity, able to live independently and mobile, without major chronic diseases, and willing to provide informed consent are ideal candidates.
✕Probably not a fit
People with diagnosed chronic diseases affecting immunity or metabolism, those using immunomodulatory or systemic anti-inflammatory medications, regular users of high-dose supplements affecting oxidative stress, or those outside the age/BMI/activity criteria are unlikely to benefit or will be excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with a BMI of 25–30 kg/m² and low-to-moderate physical activity will take either collagen peptide supplements or a placebo daily for 24 weeks. Participants attend three in-person visits at baseline, 3 months, and 6 months, when blood samples and other measurements are collected. Primary laboratory measures include telomere length and telomerase activity, alongside markers of inflammation, body composition, and functional health. The study compares changes over time between the collagen and placebo groups to determine whether collagen supplementation is associated with favorable cellular-aging outcomes.
Why it matters
Potential benefit: If successful, daily collagen supplementation could slow markers of cellular aging, lower inflammation, and support healthier body composition and function in the target group.
How similar studies have gone: While collagen supplements have some evidence for skin and joint outcomes, using collagen to affect telomere length and telomerase activity is largely novel with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 50-70 years; both male and female participants are eligible * Body mass index (BMI) 25-30 kg/m² * Low to moderate physical activity: not meeting current WHO recommendations (\<150 minutes/week) or ≤2 sessions/week structured training * Able to live independently and mobile in daily life * No regular resistance training within the past 6 months * Provision of written informed consent Exclusion Criteria: * Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases) * Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants) * Acute infections or surgeries within the last 3 months * Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D) * Participation in another clinical study within the last 3 months * Vegetarian or vegan diet (product contains animal-derived collagen)
Where it's running
-
University of Vienna, NuTraLab
Vienna, State of Vienna, Austria Recruiting
Study contacts
- Study coordinator: Daniel König, Univ. Prof. Dr.
- Email: daniel.koenig@univie.ac.at
- Phone: +43-1-4277-59130
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Observational Registry for Dezawa MuseCells Outcomes
This project follows people who were treated with Dezawa MuseCells to see how they’re doing over 5 years using online surveys.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.